Premium
Alogliptin – a new DPP‐4 inhibitor for type 2 diabetes
Author(s) -
Chaplin Steve,
Farooqi Azhar
Publication year - 2014
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1281
Subject(s) - alogliptin , medicine , type 2 diabetes , type 2 diabetes mellitus , diabetes mellitus , adverse effect , pharmacology , dipeptidyl peptidase 4 , intensive care medicine , endocrinology
Alogliptin (Vipidia), the latest DPP‐4 inhibitor, is licensed as second‐line therapy in patients with type 2 diabetes mellitus. Steve Chaplin presents the data relating to its efficacy and adverse events and Azhar Farooqi outlines its place in therapy.